This week the FDA approved the initiation of a phase III clinical trial of the oncology supportive care drug Tocilizumab (Actemra – Genentech) for the treatment of hospitalized adult patients with severe COVID-19 pneumonia. Tocilizumab is a humanized anti-interleukin (IL)-6 receptor monoclonal antibody, which blocks IL-6-mediated signal transduction. Given the crucial role of IL-6 in stimulating …
